The US FDA has issued a final authorization for the Moderna vaccine, the second vaccine for the prevention of Covid-19 caused by SARS-CoV-2. AFP
The goal is to produce up to 500 million doses of vaccines a year for the African continent, Moderna said in a statement. The focus is on drug substance manufacturing, it said, though the facility could be expanded to include fill-and-finish work.
``In parallel, Moderna is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, subject to demand,'' the company said.
The COVID-19 pandemic highlighted the huge need for vaccine manufacturing on the African continent, which remains the least-vaccinated region in the world against the coronavirus.
The continent relies on imports for about 99% of its vaccine needs, the World Health Organization has said.
Frustrated by richer nations' vaccine hoarding, African leaders joined together to pursue the goal of bringing more vaccine manufacturing to the continent of 1.3 billion people.
In October, Senegal and Rwanda signed an agreement with BioNTech for the construction of its first start-to-finish factories to make messenger RNA vaccines in Africa.
The novel mRNA process uses the genetic code for the spike protein of the coronavirus and is thought to trigger a better immune response than traditional vaccines.
Scientists hope the technology, which is easier to scale up than traditional vaccine methods, might ultimately be used to make vaccines against other diseases, including malaria.